CD79A and inflammatory bowel disease: These findings are consistent with our results and may open new avenues for the treatment of nervous system disorders by using intestinal antigens to promote IgA+B cell production and promote neuroimmune suppression (103), and thus may provide potential immunotherapy targets for patients with IBD complicated with VD.